Quantitative DCEMRI of Prostate Cancer Correlation with Gold Standards

前列腺癌的定量 DCEMRI 与金标准的相关性

基本信息

批准号：
8422144
负责人：
Gregory S. Karczmar
金额：
$ 47.17万
依托单位：
UNIVERSITY OF CHICAGO
依托单位国家：
美国
项目类别：
财政年份：
2013
资助国家：
美国
起止时间：
2013-08-01 至 2018-05-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/8422144
关键词：
Address Arteries Biological Blood Blood specimen Bolus Infusion Calibration Cancer Patient Cardiac Output Chicago Clinical Collaborations Communities Contrast Media Data Data Analyses Data Set Databases Development Diagnosis Diffusion weighted imaging Discrimination Dose Drug Kinetics Early Diagnosis Error Sources Gleason Grade for Prostate Cancer Goals Gold Histology Image In Vitro Injection of therapeutic agent Institution Letters Magnetic Resonance Imaging Malignant Neoplasms Malignant neoplasm of prostate Measurement Measures Medical Methods Morphologic artifacts Outcome Patients Phase Physiological Procedures Protocols documentation Research Research Personnel Resolution Resources Scanning Sensitivity and Specificity Source Staging System Testing Time Tissues Translations Universities anticancer research base clinical application clinical practice data acquisition design diagnostic accuracy improved in vivo innovation novel strategies public health relevance screening tool

项目摘要

DESCRIPTION (provided by applicant): Dynamic contrast enhanced MRI (DCEMRI) has potential to provide critical information to guide therapy and improve outcomes for prostate cancer (PCa) patients. However, sensitivity and specificity are not yet adequate for routine clinical use. DCEMRI has not been demonstrated to reliably differentiate between high Gleason score cancers and low Gleason score cancers. It is not known whether poor diagnostic accuracy is due to measurement error or to underlying biological variability. While a wide range of methods have been proposed to improve DCEMRI, there have been few attempts to validate these methods against gold standards, to determine whether contrast dynamics are accurately measured. To address these problems, we propose to a) Develop innovative quantitative approaches to DCEMRI that have the potential to increase diagnostic accuracy. b) Test DCEMRI against 'gold standards', to determine accuracy and variability, and guide the development of improvements that reduce error. c) Determine whether quantitative DCEMRI can improve discrimination of high Gleason grade from low Gleason grade cancers. We propose the following specific aims: 1. Quantitatively measure contrast media concentration, arterial input function, and physiological parameters (e.g. Ktrans) using innovative approaches developed at the University of Chicago. 2. Validate measurements of contrast media concentration, the arterial input function, Ktrans, and ve, using gold standard measurements, including dynamic contrast enhanced CT, direct measurements of blood concentration of contrast media, and measurements of cardiac output. 3. Evaluate variability of parameters extracted from DCEMRI data. Identify sources of variability - based on the gold-standard measurements and modify procedures to minimize variability. 4. Correlate Gleason grade with quantitative DCEMRI results. 5. Establish a curated imaging database consisting of registered multiparametric in vivo MRI, gold standard measurements, and in vitro histological images. This includes data from DCEMRI, diffusion- weighted-imaging (DWI), CT, calibration scans, parameters from quantitative analysis, and histology. This will provide researchers at other institutions with a valuable database that can be used to test quantitative analysis methods. The proposed research will provide validated DCEMRI methods that improve diagnosis and staging of Pca, and will also impact other applications of DCEMRI. The research will provide important resources for the prostate cancer research community, as evidenced by letters of support by internationally recognized experts. In addition, the collaboration with Philips Medical Systems (see letter of support) will insure rapid translation of results to clinical practice.

描述（由申请人提供）：动态对比增强 MRI (DCEMRI) 有潜力提供关键信息来指导治疗并改善前列腺癌 (PCa) 患者的预后。然而，敏感性和特异性尚不足以满足常规临床使用。 DCEMRI 尚未被证明能够可靠区分高格里森评分癌症和低格里森评分癌症。目前尚不清楚诊断准确性差是由于测量误差还是潜在的生物变异性造成的。虽然已经提出了多种方法来改进 DCEMRI，但很少有人尝试根据黄金标准验证这些方法，以确定对比度动态是否被准确测量。为了解决这些问题，我们建议 a) 开发创新的 DCEMRI 定量方法，有可能提高诊断准确性。 b) 根据“黄金标准”测试 DCEMRI，以确定准确性和可变性，并指导开发减少错误的改进措施。 c) 确定定量 DCEMRI 是否可以改善高格里森级别癌症与低格里森级别癌症的区分。我们提出以下具体目标： 1. 使用芝加哥大学开发的创新方法定量测量造影剂浓度、动脉输入功能和生理参数（例如 Ktrans）。 2. 使用黄金标准测量（包括动态对比增强 CT、直接测量造影剂血液浓度以及心输出量测量）验证造影剂浓度、动脉输入功能、Ktrans 和 ve 的测量结果。 3. 评估从 DCEMRI 数据中提取的参数的变异性。确定变异性来源 - 基于黄金标准测量并修改程序以最大程度地减少变异性。 4. 将格里森分级与定量 DCEMRI 结果相关联。 5. 建立一个由注册的多参数体内 MRI、金标准测量和体外组织学图像组成的精选成像数据库。这包括来自 DCEMRI、弥散加权成像 (DWI)、CT、校准扫描、定量分析参数和组织学的数据。这将为其他机构的研究人员提供一个有价值的数据库，可用于测试定量分析方法。拟议的研究将提供经过验证的 DCEMRI 方法，改善 Pca 的诊断和分期，并且还将影响 DCEMRI 的其他应用。该研究将为前列腺癌研究界提供重要资源，国际知名专家的支持信就证明了这一点。此外，与飞利浦医疗系统的合作（参见支持信）将确保将结果快速转化为临床实践。